Oculis Begins Registrational Trial for Precision Dry Eye Biologic
The phase 3 trial tests a precision medicine approach to DED — a category where nutraceutical and Rx crossover is inten…
The phase 3 trial tests a precision medicine approach to DED — a category where nutraceutical and Rx crossover is inten…
As global botanical ingredient demand grows, China's organized TCM forums are increasingly shaping the upstream supply …
Direct-to-consumer lab access expands the clinical addressability of metabolic liver disease — a condition increasingly…
As biologics complexity grows, contract development organizations are investing in end-to-end analytical infrastructure…
As biologics complexity grows, contract development organizations are positioning end-to-end analytical services as a c…
The expansion targets analytical and preclinical research settings — not finished formulations or consumer supplementat…
As biologics complexity grows, contract development organizations are investing in end-to-end analytical infrastructure…
A recent executive order places ibogaine among prioritized psychedelic compounds, signaling a potential regulatory path…
The RMAT designation accelerates development dialogue with FDA — a regulatory milestone operators in the immunology-adj…
The Austin-based biotech's lead candidate targets the DR3 pathway — a mechanism drawing growing interest in immune-medi…
As bioactive ingredient validation demands tighten, contract development organizations with end-to-end analytical infra…
The CDMO's integrated testing infrastructure targets a critical bottleneck in biologics development: closing the gap be…